izpis_h1_title_alt

Computational design and characterization of nanobody-derived peptides that stabilize the active conformation of the β2-adrenergic receptor (β2-AR)
ID Sencanski, Milan (Author), ID Glisic, Sanja (Author), ID Šnajder, Marko (Author), ID Veljković, Nevena (Author), ID Poklar Ulrih, Nataša (Author), ID Mavri, Janez (Author), ID Vrecl, Milka (Author)

.pdfPDF - Presentation file, Download (2,37 MB)
MD5: E1B7E895A81546ADF87578D94F6160AA
URLURL - Source URL, Visit https://www.nature.com/articles/s41598-019-52934-8 This link opens in a new window
Description: Open access

Abstract
This study aimed to design and functionally characterize peptide mimetics of the nanobody (Nb) related to the β2-adrenergic receptor (β2-AR) (nanobody-derived peptide, NDP). We postulated that the computationally derived and optimized complementarity-determining region 3 (CDR3) of Nb is sufficient for its interaction with receptor. Sequence-related Nb-families preferring the agonist-bound active conformation of β2-AR were analysed using the informational spectrum method (ISM) and β2-AR:NDP complexes studied using protein-peptide docking and molecular dynamics (MD) simulations in conjunction with metadynamics calculations of free energy binding. The selected NDP of Nb71, designated P3, was 17 amino acids long and included CDR3. Metadynamics calculations yielded a binding free energy for the β2-AR:P3 complex of ΔG = (−7.23 ± 0.04) kcal/mol, or a Kd of (7.9 ± 0.5) μM, for T = 310 K. In vitro circular dichroism (CD) spectropolarimetry and microscale thermophoresis (MST) data provided additional evidence for P3 interaction with agonist-activated β2-AR, which displayed ~10-fold higher affinity for P3 than the unstimulated receptor (MST-derived EC50 of 3.57 µM vs. 58.22 µM), while its ability to inhibit the agonist-induced interaction of β2-AR with β-arrestin 2 was less evident. In summary, theoretical and experimental evidence indicated that P3 preferentially binds agonist-activated β2-AR.

Language:English
Keywords:molecular biology, computer simulation, receptors, adrenergic, β2 – metabolism – chemistry, peptidomimetics – chemical synthesis, single-domain antibodies – chemistry
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:BF - Biotechnical Faculty
VF - Veterinary Faculty
Publication status:Published
Publication version:Version of Record
Year:2019
Number of pages:13 str.
Numbering:Vol. 9, art. 16555
PID:20.500.12556/RUL-112849 This link opens in a new window
UDC:577.2
ISSN on article:2045-2322
DOI:10.1038/s41598-019-52934-8 This link opens in a new window
COBISS.SI-ID:4896890 This link opens in a new window
Publication date in RUL:15.11.2019
Views:1063
Downloads:329
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Scientific reports
Shortened title:Sci. rep.
Publisher:Nature Publishing Group
ISSN:2045-2322
COBISS.SI-ID:18727432 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:12.11.2019

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P4-0053
Name:Endokrini, imunski in encimski odzivi pri zdravihin bolnih živalih, Biokemijska in biofizikalno-kemijska karakterizacija naravnih snovi, Molekulske simulacije in bioinformatika

Funder:ARRS - Slovenian Research Agency
Project number:P4-0121
Name:Biokemijska in biofizikalno-kemijska karakterizacija naravnih snovi

Funder:ARRS - Slovenian Research Agency
Project number:P1-0012
Name:Molekulske simulacije, bioinformatika in načrtovanje zdravilnih učinkovin

Funder:MESTD - Ministry of Education, Science and Technological Development of Republic of Serbia
Funding programme:Basic Research (BR or ON)
Project number:173001
Name:Application of the EIIP/ISM bioinformatics platform in discovery of novel therapeutic targets and potential therapeutic molecules

Funder:EC - European Commission
Funding programme:Horizon 2020
Project number:CA 18133
Acronym:ERNEST

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back